Martin S. Tallman, MD, chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of midostaurin (PKC412) for adult patients with newly diagnosed 

Videos

Martin S. Tallman, MD, chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).

Dr. Tallman on FDA Approval of Midostaurin in AML

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regard to treatment of patients with acute myeloid leukemia (AML).

The state of the art rests on a number of principles, Tallman explains. First, the disease is truly defined today by cytogenetic and molecular or genomic abnormalities. Second, induction chemotherapy can be intensified for the benefit of patients, Tallman explains. Third, consolidation treatment may be able to be deintensified. Fourth, the benefit of allogeneic transplantation has only increased over time; also, there has been an expanded pool of patients who may benefit from transplantation.

Fifth, there is an increasing awareness of the importance of minimal residual disease studies, both following intensive chemotherapy and before allogeneic transplantation. Perhaps the most exciting advance, he adds, is the development of new agents that are very promising in the treatment of AML today.

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).

Dr. Tallman on the State of the Science in AML Treatment

Martin S. Tallman, MD, Chief, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of hairy cell leukemia (HCL) with a BRAF inhibitor.

HCL is an uncommon disease, with fewer than 1,000 new diagnoses per year in the U.S. It was recently reported, Tallman says, that most patients with HCL have a BRAF mutation. At Memorial Sloan-Kettering Cancer Center, researchers are looking at vemurafenib, a BRAF inhibitor, in patients with relapsed/refractory HCL. Tallman says they are encouraged by initial results.

Martin S. Tallman, MD

Articles

Dr. Tallman on FDA Approval of Midostaurin in AML

Dr. Tallman on the State of the Science in AML Treatment

Dr. Tallman on BRAF Inhibitors for the Treatment of HCL